Table 2 Tumor characteristics and staging among controls (M0) and women affected by peritoneal carcinomatosis (M1: peritoneum) or other site of metastases (M1: other than peritoneum)
From: Prevalence, risk factors, and prognosis of peritoneal metastasis from breast cancer
M0 | M1 | M1 | p | |
|---|---|---|---|---|
Other than peritoneum | Peritoneum | |||
Histological type | ||||
Ductal invasive carcinoma | 77.4 % (2173/2807) | 66.7 % (178/267) | 50 % (11/22) | (1, 2) |
Lobular invasive carcinoma | 12.1 % (340/2807) | 16.5 % (44/267) | 36.4 % (8/22) | (1, 2, 3) |
Ductal and lobular invasive carcinoma | 6.7 % (189/2807) | 12.7 % (34/267) | 9.1 % (2/22) | (1) |
Other invasive carcinoma | 3.7 % (105/2807) | 4.1 % (11/267) | 4.5 % (1/22) | NS |
Molecular Subtype | ||||
Luminal A | 32.9 % (923/2807) | 13.5 % (36/267) | 31.8 % (7/22) | (1, 3) |
Luminal B | 23.2 % (652/2807) | 29.6 % (79/267) | 31.8 % (7/22) | (1) |
Luminal Her | 5.5 % (153/2807) | 8.2 % (22/267) | 9.1 % (2/22) | (1*) |
Her enriched | 4 % (111/2807) | 8.6 % (23/267) | 0 % (0/22) | (1) |
Basal-like | 7.3 % (205/2807) | 16.5 % (44/267) | 9.1 % (2/22) | (1) |
Non described | 27.2 % (763/2807) | 23.6 % (63/267) | 18.2 % (4/22) | NS |
Other characteristics of the primary tumor | ||||
ER positives | 85.2 % (2284/2680) | 71.7 % (180/251) | 90.9 % (20/22) | (1, 3*) |
PgR positives | 73 % (1958/2681) | 55.8 % (140/251) | 59.1 % (13/22) | (1) |
HER2/neu positives | 11.8 % (267/2254) | 19.4 % (45/232) | 9.5 % (2/21) | (1) |
Ki-67/Mib-1 >20 | 33.7 % (671/1994) | 61.1 % (113/185) | 29.4 % (5/17) | (1, 3) |
Comedo-like necrosis | 8.7 % (243/2807) | 7.9 % (21/267) | 0 % (0/22) | NS |
Multifocality/multicentricity | 20.2 % (567/2807) | 22.5 % (60/267) | 18.2 % (4/22) | NS |
Extensive intraductal component | 27.2 % (764/2807) | 21.3 % (57/267) | 13.6 % (3/22) | (1) |
Lymphovascular invasion | 15.6 % (439/2807) | 26.6 % (71/267) | 18.2 % (4/22) | (1) |
Peritumoral inflammation | 3.3 % (93/2807) | 9.4 % (25/267) | 0 % (0/22) | (1) |
Loco-regional lymph nodes characteristics | ||||
Non-axillary loco-regional lymph nodes | 1.7 % (48/2807) | 1.5 % (4/267) | 0 % (0/22) | NS |
Isolated tumor cells | 2 % (56/2807) | 0.4 % (1/267) | 0 % (0/22) | (1**) |
Micrometastases | 4.9 % (138/2807) | 4.1 % (11/267) | 4.5 % (1/22) | NS |
Extracapsular invasion of lymph node metastasis | 7.1 % (198/2807) | 28.1 % (75/267) | 36.4 % (8/22) | (1, 2) |
Bunched axillary lymph nodes | 2.1 % (58/2807) | 18 % (48/267) | 31.8 % (7/22) | (1, 2) |
TNM | ||||
T1 | 75.4 % (2116/2807) | 41.2 % (110/267) | 68.2 % (15/22) | (1,3) |
T2 | 20.9 % (586/2807) | 37.8 % (101/267) | 13.6 % (3/22) | (1, 3**) |
T3 | 1.6 % (44/2807) | 10.1 % (27/267) | 4.5 % (1/22) | (1) |
T4 | 2.2 % (61/2807) | 10.9 % (29/267) | 13.6 % (3/22) | (1, 2) |
N0 | 69.9 % (1961/2807) | 32.6 % (87/267) | 36.4 % (8/22) | (1, 2) |
N1 | 21.2 % (594/2807) | 23.2 % (62/267) | 13.6 % (3/22) | NS |
N2 | 5.3 % (150/2807) | 17.2 % (46/267) | 9.1 % (2/22) | (1) |
N3 | 3.6 % (102/2807) | 27 % (72/267) | 40.9 % (9/22) | (1, 2) |
Grading | ||||
G1 | 15.8 % (444/2807) | 2.6 % (7/267) | 0 % (0/22) | (1, 2) |
G2 | 60.3 % (1693/2807) | 49.8 % (133/267) | 90.9 % (20/22) | (1, 2, 3) |
G3 | 23.9 % (670/2807) | 47.6 % (127/267) | 9.1 % (2/22) | (1, 3) |